- According to estimates from 9 analysts, Ligand Pharmaceuticals Incorporated stock's average price target has risen from $285.67 to $299.22, with forecasts ranging from $247 to $388 per share
- Based on the Jul. 8 closing price, the updated target implies approximately 5% potential downside
- Consensus rating remains at “Buy” across 8 covering analysts, with 8 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Ligand Pharmaceuticals Incorporated on the , and track all previous and future analyst recommendations for Ligand Pharmaceuticals Incorporated in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.